Amgen (AMGN) Modestly Higher Into Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amgen (AMGN) Price Target Raised to $195 at Jefferies
April 22, 2015 11:41 AM EDTIn a note earlier, Jefferies analyst Eun K. Yang reiterated a Buy rating and boosted his price target on Amgen (NASDAQ: AMGN) to $195.00 (from $182.00) following Q1 results.
Yang commented, "Reported ~18% higher EPS (vs. cons) on ~3% higher product sales & lower OpEx; upped FY15 EPS guidance... More
Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook
April 21, 2015 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.48, $0.38 better than the analyst estimate of $2.10. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.91 billion.
Amgen sees FY2015 EPS of $9.35 - $9.65, versus the consensus of $9.32. Amgen sees FY2015 revenue of $20.9 - $21.3... More
